13-Nov-2024	Marcus Today On the Couch podcast with Jon Pilcher

25-Oct-2024	ASX CEO Connect

16-Oct-2024	ShareCafe Small Cap Hidden Gems Presentation

8-Nov-2023	ASX article, 8 Nov 2023

20-Oct-2023	Neuren receives Australian Growth Company of the Year Award

26-May-2023	IRSF Physician Panel: Answering Your Questions About Trofinetide

15-May-2023	IRSF Parent Panel: My Trofinetide Clinical Trial Experience

20-Mar-2023	Proactive interview, 20 March 2023

14-Mar-2023	Ausbiz interview, 14 March 2023

13-Mar-2023	Finance News Network interview, 13 March 2023

10-Nov-2022	Neuren on Marcus Today Podcast, 7 Nov 2022

14-Sep-2022	Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference

24-Jun-2022	AusBiz interview 22 June 2022

4-Apr-2022	Australian Financial Review article 4 Apr 2022

10-Dec-2021	AusBiz interview 8 December 2021

2-Jul-2021	Peak TV interview 2 July 2021

12-Jan-2021	Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591

19-Nov-2020	Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial

4-Mar-2020	Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome

5-Dec-2017	Neuren Pharmaceuticals gets green light for a patent in the U.S.

29-Jun-2017	Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials

22-Mar-2017	Neuren Pharmaceuticals drug shows promise in treating Rett syndrome

19-Mar-2017	Neuren Pharmaceuticals granted ASX trading halt pending trial update

25-Aug-2016	Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome

27-Jun-2016	Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome

22-Apr-2016	Neuren Pharmaceuticals Ltd to reveal clinical results

30-Dec-2014	Neuren Pharmaceuticals seeks “orphan drug” status for Rett Syndrome treatment

12-Nov-2014	Neuren Pharmaceuticals makes Rett Syndrome trial breakthrough

10-Nov-2014	Neuren Pharmaceuticals granted halt pending trial results

8-Sep-2014	Neuren Pharmaceuticals to enrol subjects for concussion trial

18-Jul-2014	Neuren Pharmaceuticals gains increased funding for brain injury drug trials

26-Jun-2014	Neuren Pharmaceuticals completes enrolment for Rett Syndrome clinical trial

28-Jan-2014	Neuren Pharmaceuticals progresses Phase 2 trials for brain treatment drug

21-Nov-2013	Neuren Pharmaceuticals' shares trade heavy volume

22-Oct-2013	Neuren Pharmaceuticals raises $21.5M to commercialise brain treatment drugs

18-Oct-2013	Neuren Pharmaceuticals launches capital raising

9-Sep-2013	Neuren Pharmaceuticals gets nod from FDA to trial new drug for Autism

14-Aug-2013	Neuren Pharmaceuticals cranks up the volume with 11 million shares traded

5-Aug-2013	Neuren Pharmaceuticals in pre-open to address market chatter

12-Jul-2013	Neuren Pharmaceuticals receives notice of allowance by USPTO for neuropathy patents

24-Dec-2012	Neuren Pharmaceuticals given US approval for clinical trial of Rett Syndrome drug

25-Oct-2012	Neuren Pharmaceuticals’ 53% share price jump prompts ASX query

6-Jul-2012	Neuren Pharmaceuticals gains grant for Phase 2 trials of Neuren Rett Syndrome treatment

20-Oct-2011	Neuren Pharmaceuticals responds to ASX after 81% spike prompts price query

19-May-2011	Neuren Pharmaceuticals to begin testing antibodies used for cancer treatment

11-May-2011	Neuren Pharmaceuticals progresses post-brain injury drug in clinical trials